Top
Summary
All studies
Hospitalization
Serious outcomes
Recovery
RCTs
Peer-reviewed
All outcomes

Feedback
Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
All acebilustat studies
 
Feedback
Home
c19early.org COVID-19 treatment researchAcebilustatAcebilustat (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Outcomes in COVID-19 acebilustat studies

0 0.5 1 1.5+ All studies 0% 1 120 Improvement, Studies, Patients Relative Risk Hospitalization 0% 1 120 RCTs 0% 1 120 Early 0% 1 120 Acebilustat for COVID-19 c19early.org July 2024 Favorsacebilustat Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Levitt (DB RCT) 0% 1.00 [0.06-15.6] hosp. 1/60 1/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Early treatment 0% 1.00 [0.06-15.6] 1/60 1/60 no change All studies 0% 1.00 [0.06-15.6] 1/60 1/60 no change 1 acebilustat COVID-19 study c19early.org July 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors acebilustat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Levitt (DB RCT) 0% 1.00 [0.06-15.6] hosp. 1/60 1/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Early treatment 0% 1.00 [0.06-15.6] 1/60 1/60 no change All studies 0% 1.00 [0.06-15.6] 1/60 1/60 no change 1 acebilustat COVID-19 hospitalization result c19early.org July 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Favors acebilustat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Levitt (DB RCT) 0% 1.00 [0.06-15.6] hosp. 1/60 1/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Early treatment 0% 1.00 [0.06-15.6] 1/60 1/60 no change All studies 0% 1.00 [0.06-15.6] 1/60 1/60 no change 1 acebilustat COVID-19 serious outcome c19early.org July 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors acebilustat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Levitt (DB RCT) -67% 1.67 [0.96-2.94] no recov. 60 (n) 60 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.07 Early treatment -67% 1.67 [0.96-2.94] 60 (n) 60 (n) 67% higher risk All studies -67% 1.67 [0.96-2.94] 60 (n) 60 (n) 67% higher risk 1 acebilustat COVID-19 recovery result c19early.org July 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.07 Favors acebilustat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Levitt (DB RCT) 0% 1.00 [0.06-15.6] hosp. 1/60 1/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Early treatment 0% 1.00 [0.06-15.6] 1/60 1/60 no change All studies 0% 1.00 [0.06-15.6] 1/60 1/60 no change 1 acebilustat COVID-19 Randomized Controlled Trials c19early.org July 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors acebilustat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Levitt (DB RCT) 0% 1.00 [0.06-15.6] hosp. 1/60 1/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Early treatment 0% 1.00 [0.06-15.6] 1/60 1/60 no change All studies 0% 1.00 [0.06-15.6] 1/60 1/60 no change 1 acebilustat COVID-19 peer reviewed studies c19early.org July 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors acebilustat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Levitt (DB RCT) 0% 1.00 [0.06-15.6] hosp. 1/60 1/60 Improvement, RR [CI] Treatment Control Levitt (DB RCT) 80% 0.20 [0.02-1.66] progression 1/60 5/60 Levitt (DB RCT) -67% 1.67 [0.96-2.94] no recov. 60 (n) 60 (n) Levitt (DB RCT) -61% 1.61 [0.99-2.63] no recov. 60 (n) 60 (n) Acebilustat COVID-19 outcomes c19early.org July 2024 Favors acebilustat Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit